ACRIN-NSCLC-FDG-PET

Thirty-seven institutions accrued 250 patients to the study ACRIN 6668. Eligible patients were >18 years with AJCC-criteria clinical stage IIB/III non-small cell lung carcinoma who were being planned for definitive concurrent chemoradiotherapy (inoperable disease). 173 had evaluable post-treatment PET, representing the analysis cohort for the primary end point. Please see the ACRIN-NSCLC-FDG-PET wiki page to learn more about the images and to obtain any supporting metadata for this collection.